| Literature DB >> 26427345 |
Challise J Sullivan1, Erik D Pendleton1, Henri H Sasmor1, William L Hicks1, John B Farnum2, Machiko Muto2, Eric M Amendt1, Jennifer A Schoborg3, Rey W Martin3, Lauren G Clark3, Mark J Anderson3, Alaksh Choudhury3, Raffaella Fior4, Yu-Hwa Lo4, Richard H Griffey1, Stephen A Chappell2, Michael C Jewett3, Vincent P Mauro2, John Dresios5.
Abstract
Cell-free protein synthesis has emerged as a powerful technology for rapid and efficient protein production. Cell-free methods are also amenable to automation and such systems have been extensively used for high-throughput protein production and screening; however, current fluidic systems are not adequate for manufacturing protein biopharmaceuticals. In this work, we report on the initial development of a fluidic process for rapid end-to-end production of recombinant protein biologics. This process incorporates a bioreactor module that can be used with eukaryotic or prokaryotic lysates that are programmed for combined transcription/translation of an engineered DNA template encoding for specific protein targets. Purification of the cell-free expressed product occurs through a series of protein separation modules that are configurable for process-specific isolation of different proteins. Using this approach, we demonstrate production of two bioactive human protein therapeutics, erythropoietin and granulocyte-macrophage colony-stimulating factor, in yeast and bacterial extracts, respectively, each within 24 hours. This process is flexible, scalable and amenable to automation for rapid production at the point-of-need of proteins with significant pharmaceutical, medical, or biotechnological value.Entities:
Keywords: Cell-free protein synthesis; Granulocyte-macrophage colony-stimulating factor; Protein Biologics; Protein expression
Mesh:
Substances:
Year: 2015 PMID: 26427345 DOI: 10.1002/biot.201500214
Source DB: PubMed Journal: Biotechnol J ISSN: 1860-6768 Impact factor: 4.677